Ultragenyx Pharmaceutical (RARE) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Ultragenyx Pharmaceutical (RARE) right now is Near-term gene therapy approvals: Two gene therapies are under FDA review with 2026 decision dates: DTX401 for glycogen storage disease type Ia and UX111 for Sanfilippo syndrome type A. Revenue (TTM) is ~$670M. If that keeps playing out, the setup is favourable; the risk to it is ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. No one can predict where RARE trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Ultragenyx Pharmaceutical (RARE) higher?
1. Near-term gene therapy approvals
Two gene therapies are under FDA review with 2026 decision dates: DTX401 for glycogen storage disease type Ia and UX111 for Sanfilippo syndrome type A. Both target diseases with no approved therapies, giving Ultragenyx a potential first-mover position. Approvals could also unlock sellable priority review vouchers that management is counting on for cash.
2. Angelman syndrome readout
Pivotal Phase 3 Aspire data for GTX-102 in Angelman syndrome is expected in the second half of 2026. Angelman is a large opportunity relative to Ultragenyx's typical ultra-rare markets, so a positive readout would materially expand the addressable pipeline. It is also one of the highest-risk binary events on the calendar.
3. Growing commercial base
Crysvita, guided to roughly $500 million to $520 million in 2026, anchors a portfolio that management expects to keep growing at a high-single to low-double-digit rate. A steady base business helps fund the pipeline and supports the stated 2027 profitability target. Dojolvi and Evkeeza add incremental, if smaller, contribution.
4. Cost discipline toward profitability
Ultragenyx cut about 10% of its workforce and guided 2026 R&D and SG&A to be flat-to-down as it concentrates resources on near-term launches. The restructuring is meant to preserve cash and make the 2027 profitability goal credible. Execution on this cost curve is central to the equity story.
What could weigh on RARE?
Ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. The value concentrated in binary regulatory and clinical events (DTX401, UX111, and especially the GTX-102 Angelman readout) means a single negative outcome could sharply move the stock. Rare-disease revenue depends on small patient counts, payer reimbursement, and diagnosis rates, all of which can disappoint. The company faces well-capitalized competitors in gene therapy and orphan drugs, including BioMarin, Sarepta, and larger players. Finally, the 2027 profitability target is a management objective, not a guarantee, and could slip.
Where RARE trades today
A forecast starts from where the stock actually is. These are RARE's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for RARE as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a RARE forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the RARE guide and whether RARE is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the RARE outlook
The bottom line: what is driving Ultragenyx Pharmaceutical (RARE) is Near-term gene therapy approvals, with revenue (ttm) at ~$670M. If that keeps playing out the setup is favourable; the risk is ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. No one can predict the price, so treat any RARE forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around RARE with Walnut
Use Ultragenyx Pharmaceutical as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Ultragenyx Pharmaceutical (RARE)?
+
No one can reliably predict where RARE will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Ultragenyx Pharmaceutical higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive RARE higher?
+
The main growth drivers are Near-term gene therapy approvals; Angelman syndrome readout; Growing commercial base. Whether they play out is the real question, not a guaranteed path.
What are the risks to RARE?
+
Ultragenyx remains unprofitable, with a net loss of about $575 million in 2025 and roughly $737 million of cash as of December 2025, so continued spending or delayed approvals could pressure the balance sheet and raise dilution or financing risk. The value concentrated in binary regulatory and clinical events (DTX401, UX111, and especially the GTX-102 Angelman readout) means a single negative outcome could sharply move the stock. Rare-disease revenue depends on small patient counts, payer reimbursement, and diagnosis rates, all of which can disappoint. The company faces well-capitalized competitors in gene therapy and orphan drugs, including BioMarin, Sarepta, and larger players. Finally, the 2027 profitability target is a management objective, not a guarantee, and could slip.
Will RARE stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Ultragenyx Pharmaceutical's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is RARE a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the RARE "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.